AstraZeneca, Bumble, McDonald’s, Microsoft and More Monday Afternoon Analyst Calls
- By247wallst-
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including AstraZeneca, Bumble, McDonald’s and Microsoft.
Farxiga (dapagliflozin)has failed to achieve the primaryendpoint with statistical significance in a Phase 3 randomized trial of hospitalized COVID-19 patients who are at risk of...
Vaccitech PLC said it plans to use the technology underpinning the vaccine to develop treatments targeting prostate cancer, hepatitis B and human papillomavirus.
The Fed downplayed inflation concernsSPX hit a new record closeBitcoin rallies above $57,000Key EventsMinutes from the previous Federal Reserve meeting, released Wednesday,...
UK Slaps Restrictions On AstraZeneca Jab Despite Insisting It Is "Safe For All Ages"Now that the EMA has acknowledged a "possible link" between the AstraZeneca vaccine and the...
Watch Live: EMA Delivers Update On AstraZeneca Jab After Acknowledging Blood-Clot LinkWeeks after its initial "safety review", where the EMA insisted that the risks posed by the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Strong Sell | Strong Sell | Neutral |
| Technical Indicators | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Sell | Strong Sell | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 244.01 | 244.91 | 236.65 | +20.70 | +9.27% | 57.50M | NYSE | |||
| 70.86 | 71.84 | 69.65 | -0.33 | -0.46% | 9.50M | NYSE | |||
| 114.39 | 116.10 | 111.34 | -1.35 | -1.17% | 1.08M | NASDAQ | |||
| 214.14 | 219.12 | 211.56 | -5.53 | -2.52% | 8.17M | NASDAQ | |||
| 21.65 | 22.54 | 21.03 | -1.79 | -7.64% | 859.16K | NASDAQ | |||
| 7.92 | 8.05 | 7.88 | -0.16 | -1.98% | 2.71M | NYSE | |||
| 12.28 | 12.31 | 12.22 | -0.01 | -0.08% | 313.58K | NYSE | |||
| 29.68 | 31.46 | 28.77 | -2.62 | -8.11% | 43.88M | NASDAQ | |||
| 17.19 | 18.21 | 17.10 | -2.57 | -13.01% | 27.25M | NASDAQ | |||
| 11.04 | 11.49 | 11.00 | -0.47 | -4.08% | 344.92K | NYSE | |||
| 129.43 | 129.83 | 122.80 | +1.55 | +1.21% | 31.02K | NASDAQ | |||
| 44.03 | 44.03 | 44.03 | -1.44 | -3.17% | 0.23K | OTC Markets | |||
| 3.07 | 3.37 | 3.01 | -0.280 | -8.36% | 525.53K | NASDAQ | |||
| 45.22 | 46.02 | 44.40 | -0.63 | -1.37% | 3.67M | NYSE | |||
| 19.00 | 19.11 | 18.80 | -0.655 | -3.33% | 282.24K | OTC Markets |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.